Hidden Drug Resistant HIV to Emerge in the Era of Universal Treatment Access in Southeast Asia

Background Universal access to first-line antiretroviral therapy (ART) for HIV infection is becoming more of a reality in most low and middle income countries in Asia. However, second-line therapies are relatively scarce. Methods and Findings We developed a mathematical model of an HIV epidemic in a Southeast Asian setting and used it to forecast the impact of treatment plans, without second-line options, on the potential degree of acquisition and transmission of drug resistant HIV strains. We show that after 10 years of universal treatment access, up to 20% of treatment-naïve individuals with HIV may have drug-resistant strains but it depends on the relative fitness of viral strains. Conclusions If viral load testing of people on ART is carried out on a yearly basis and virological failure leads to effective second-line therapy, then transmitted drug resistance could be reduced by 80%. Greater efforts are required for minimizing first-line failure, to detect virological failure earlier, and to procure access to second-line therapies.

[1]  Praphan Phanuphak,et al.  Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010 , 2010 .

[2]  D. Pillay,et al.  Transmission of HIV-1 drug resistance. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  Wiwat Rojanapithayakorn,et al.  The 100% Condom Use Programme in Asia , 2006, Reproductive health matters.

[4]  K. Ruxrungtham,et al.  Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor‐naïve, nonnucleoside reverse transcriptase inhibitor‐experienced patients: study TMC125‐C227 * , 2008, HIV medicine.

[5]  T Brown,et al.  The Asian Epidemic Model: a process model for exploring HIV policy and programme alternatives in Asia , 2004, Sexually Transmitted Infections.

[6]  K. Ruxrungtham,et al.  High Rate Multiple Drug Resistances in HIV-Infected Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Regimens in Thailand, Where Subtype A/E is Predominant , 2006, Journal of the International Association of Physicians in AIDS Care.

[7]  Sung Soon Kim,et al.  National Survey for Drug-Resistant Variants in Newly Diagnosed Antiretroviral Drug-Naive Patients With HIV/AIDS in South Korea: 1999-2005 , 2008, Journal of acquired immune deficiency syndromes.

[8]  Hsin-Yun Sun,et al.  Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. , 2008, The Journal of antimicrobial chemotherapy.

[9]  D. Bangsberg,et al.  Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. , 2004, The Journal of infectious diseases.

[10]  K. Ruxrungtham,et al.  HIV drug resistance transmission threshold survey in Bangkok, Thailand , 2008, Antiviral therapy.

[11]  A. Apisarnthanarak,et al.  Antiretroviral drug resistance among antiretroviral‐naïve persons with recent HIV infection in Thailand , 2008, HIV medicine.

[12]  A. Geretti,et al.  Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.

[13]  Erin N. Bodine,et al.  The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. , 2005, AIDS.

[14]  M. Law,et al.  Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD) , 2007, AIDS research and therapy.

[15]  Anne-Mieke Vandamme,et al.  No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  W. Sugiura,et al.  Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. , 2007, Antiviral research.

[17]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[18]  C. Boucher,et al.  Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 1999, Journal of Clinical Microbiology.

[19]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[20]  U. Siangphoe,et al.  National Expansion of Antiretroviral Treatment in Thailand, 2000-2007: Program Scale-Up and Patient Outcomes , 2009, Journal of acquired immune deficiency syndromes.

[21]  P. Harrigan,et al.  Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART , 2006, PLoS medicine.

[22]  P. Harrigan,et al.  Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness , 2006, AIDS.

[23]  T. Brown,et al.  HIV/AIDS in Asia , 2003, The Lancet.

[24]  D. Kempf,et al.  Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. , 2005, The Journal of infectious diseases.

[25]  A. Zolopa,et al.  High levels of adherence do not prevent accumulation of HIV drug resistance mutations , 2003, AIDS.

[26]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[27]  Sally Blower,et al.  Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. , 2003, Current drug targets. Infectious disorders.

[28]  S. Blower,et al.  Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: The effect of the urban–rural divide , 2006, Proceedings of the National Academy of Sciences.

[29]  Sa Azin,et al.  An overview on the 2008 UNAIDS Report on the 2008 UNAIDS Report on the Global AIDS Epidemic. , 2010 .

[30]  F. Maggiolo,et al.  Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients , 2007, HIV clinical trials.

[31]  Organización Mundial de la Salud,et al.  Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009 , 2009 .

[32]  Y. Lo,et al.  The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand. , 2006, The Southeast Asian journal of tropical medicine and public health.

[33]  A. Vibhagool,et al.  The TREAT Asia HIV Observational Database: Baseline and Retrospective Data , 2005, Journal of acquired immune deficiency syndromes.

[34]  T. Puthanakit,et al.  Predictors of Virologic Failure and Genotypic Resistance Mutation Patterns in Thai Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy , 2009, The Pediatric infectious disease journal.

[35]  B. Gazzard,et al.  Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study , 2007, The Lancet.

[36]  K. Ungchusak,et al.  The epidemiology of HIV infection and AIDS in Thailand. , 1991, AIDS.

[37]  Wasun Chantratita,et al.  Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  K. Fennie,et al.  Adherence to Antiretroviral Medication Among HIV-Positive Patients in Thailand , 2006, Journal of acquired immune deficiency syndromes.

[39]  P. Harrigan,et al.  The Relationship Between Resistance and Adherence in Drug-Naive Individuals Initiating HAART Is Specific to Individual Drug Classes , 2008, Journal of acquired immune deficiency syndromes.

[40]  R. Schooley,et al.  High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  P. Harrigan,et al.  Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. , 2005, The Journal of infectious diseases.

[42]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[43]  A. Apisarnthanarak,et al.  Antiretroviral drug resistance among antiretroviral-naive individuals with HIV infection of unknown duration in Thailand. , 2008, Clinical Infectious Diseases.

[44]  Hadi Dowlatabadi,et al.  Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example , 1994 .

[45]  James Curran,et al.  Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .

[46]  Julio S. G. Montaner,et al.  Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 109 cells/L , 2003, Annals of Internal Medicine.

[47]  Matthew G Law,et al.  Relation between HIV viral load and infectiousness: a model-based analysis , 2008, The Lancet.

[48]  G. Cohen Access to diagnostics in support of HIV/AIDS and tuberculosis treatment in developing countries , 2007, AIDS.

[49]  J. H. Chen,et al.  Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[50]  David P Wilson,et al.  Sampling and sensitivity analyses tools (SaSAT) for computational modelling , 2008, Theoretical Biology and Medical Modelling.

[51]  M. S. Sánchez,et al.  A decrease in drug resistance levels of the HIV epidemic can be bad news , 2005, Bulletin of mathematical biology.

[52]  B. Gazzard,et al.  Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice , 2005, AIDS.

[53]  Rodolphe Thiébaut,et al.  Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy , 2008, AIDS.

[54]  Matthias Egger,et al.  Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis , 2009, AIDS.